Skip to main content

Home/ Nutrition/ Group items tagged clinical_trial patients

Rss Feed Group items tagged

Matti Narkia

Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients... - 0 views

  •  
    Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy.
    Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U.
    Circulation. 2009 Dec 21. [Epub ahead of print]
    PMID: 20026785
    doi: 10.1161/CIRCULATIONAHA.108.836346

    Conclusions-HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL from healthy subjects. ER niacin therapy not only increases HDL plasma levels but markedly improves endothelial-protective functions of HDL in these patients, which is potentially more important.
Matti Narkia

NEJM -- Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness - 0 views

  •  
    Extended-release niacin or ezetimibe and carotid intima-media thickness.
    Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M.
    N Engl J Med. 2009 Nov 26;361(22):2113-22. Epub 2009 Nov 15.
    PMID: 19915217

    Conclusions This comparative-effectiveness trial shows that the use of extended-release niacin causes a significant regression of carotid intima-media thickness when combined with a statin and that niacin is superior to ezetimibe. (ClinicalTrials.gov number, NCT00397657 [ClinicalTrials.gov] .
Matti Narkia

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocar... - 0 views

  •  
    Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
    [No authors listed]
    Lancet. 1999 Aug 7;354(9177):447-55. Erratum in: Lancet 2001 Feb 24;357(9256):642. Lancet. 2007 Jan 13;369(9556):106.
    PMID: 10465168

    Interpretation
    Dietary supplementation with n-3 PUFA led to a clinically important and satistically significant benefit. Vitamin E had no benefit. Its effects on fatal cardiovascular events require further exploration
Matti Narkia

Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing ... - 0 views

  •  
    Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
    Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD.
    Metabolism. 2009 Sep 3
    doi:10.1016/j.metabol.2009.07.029

    Liver function was improved greatly in these patients by showing reduction of liver enzymes. Our results confirmed the activity of BBR on InsR in humans and its relationship with the glucose-lowering effect. Together with our previous report, we strongly suggest BBR as an ideal medicine for T2DM with a mechanism different from metformin and rosiglitazone.
Matti Narkia

Efficacy and safety of berberine for congestive heart failure secondary to ischemic or ... - 1 views

  •  
    Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Zeng XH, Zeng XJ, Li YY.
    Am J Cardiol. 2003 Jul 15;92(2):173-6.
    PMID: 12860219
    doi:10.1016/S0002-9149(03)00533-2

    Thus, berberine improved quality of life and decreased VPCs and mortality in patients with CHF.
Matti Narkia

Efficacy of Berberine in Patients with Type 2 Diabetes - 0 views

  •  
    Efficacy of berberine in patients with type 2 diabetes mellitus.
    Yin J, Xing H, Ye J.
    Metabolism. 2008 May;57(5):712-7.
    PMID: 18442638
    doi: 10.1016/j.metabol.2008.01.013.

    Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively. Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well. During the trial, 20 (34.5%) patients experienced transient gastrointestinal adverse effects. Functional liver or kidney damages were not observed for all patients. In conclusion, this pilot study indicates that berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism

    In summary, that berberine is a potent oral hypoglycemic agent with modest effect on lipid metabolism. It is safe and the cost of treatment by berberine is very low. It may serve as a new drug candidate in the treatment of type 2 diabetes. However, this is a pilot study. The efficacy of berberine needs to be tested in a much larger population and characterized as a function of the known duration of the diabetes. Further studies are needed to evaluate the action of berberine on type 2 diabetes in other ethnic groups.
Matti Narkia

Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumul... - 0 views

  •  
    Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
    Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H.
    J Hepatol. 2009 Aug;51(2):315-21. Epub 2009 May 15.
    PMID: 19501932

    CONCLUSIONS: The combination treatment of VK and ACE-I may suppress the cumulative recurrence of HCC after the curative therapy, at least partly through suppression of the VEGF-mediated neovascularization.
Matti Narkia

Berberine is a novel cholesterol-lowering drug working through a unique mechanism disti... - 0 views

  •  
    Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
    Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD.
    Nat Med. 2004 Dec;10(12):1344-51. Epub 2004 Nov 7.
    PMID: 15531889
    doi:10.1038/nm1135

    We identify berberine (BBR), a compound isolated from a Chinese herb, as a new cholesterol-lowering drug. Oral administration of BBR in 32 hypercholesterolemic patients for 3 months reduced serum cholesterol by 29%, triglycerides by 35% and LDL-cholesterol by 25%. Treatment of hyperlipidemic hamsters with BBR reduced serum cholesterol by 40% and LDL-cholesterol by 42%, with a 3.5-fold increase in hepatic LDLR mRNA and a 2.6-fold increase in hepatic LDLR protein. Using human hepatoma cells, we show that BBR upregulates LDLR expression independent of sterol regulatory element binding proteins, but dependent on ERK activation. BBR elevates LDLR expression through a post-transcriptional mechanism that stabilizes the mRNA. Using a heterologous system with luciferase as a reporter, we further identify the 5' proximal section of the LDLR mRNA 3' untranslated region responsible for the regulatory effect of BBR. These findings show BBR as a new hypolipidemic drug with a mechanism of action different from that of statin drugs.
Matti Narkia

Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine... - 0 views

  •  
    Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.
    Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G.
    J Clin Endocrinol Metab. 2008 Jul;93(7):2559-65. Epub 2008 Apr 8.
    PMID: 18397984
    doi:10.1210/jc.2007-2404

    Conclusions: Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia.
Matti Narkia

Corrigendum to "Omega-3 fatty acids in major depressive disorder A preliminary double-b... - 0 views

  •  
    Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.
    Su KP, Huang SY, Chiu CC, Shen WW.
    Eur Neuropsychopharmacol. 2003 Aug;13(4):267-71. Erratum in: Eur Neuropsychopharmacol. 2004 Mar;14(2):173.
    PMID: 12888186

    From the preliminary findings in this study, omega-3 PUFAs could improve the short-term course of illness and were well tolerated in patients in major depressive disorder.
Matti Narkia

Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in... - 0 views

  •  
    Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial.
    Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gicchino M, Petrizzo M, Saccomanno F, Beneduce F, Ceriello A, Giugliano D.
    Ann Intern Med. 2009 Sep 1;151(5):306-14. Erratum in: Ann Intern Med. 2009 Oct 20;151(8):591.
    PMID: 19721018

    Conclusion: Compared with a low-fat diet, a low-carbohydrate, Mediterranean-style diet led to more favorable changes in glycemic control and coronary risk factors and delayed the need for antihyperglycemic drug therapy in overweight patients with newly diagnosed type 2 diabetes.
Matti Narkia

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in brea... - 0 views

  •  
    A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases.
    Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M.
    Cancer. 2009 Nov 13. [Epub ahead of print]
    PMID: 19918922
    DOI: 10.1002/cncr.24749

    METHODS:
    Patients with bone metastases treated with bisphosphonates were enrolled into this single-arm phase 2 study. Patients received 10,000 IU of vitamin D3 and 1000 mg of calcium supplementation each day for 4 months. The effect of this treatment on palliation, bone resorption markers, calcium metabolism, and toxicity were evaluated at baseline and monthly thereafter.


    CONCLUSIONS:
    Daily doses of 10,000 IU vitamin D3 for 4 months appear safe in patients without comorbid conditions causing hypersensitivity to vitamin D. Treatment reduced inappropriately elevated parathyroid hormone levels, presumably caused by long-term bisphosphonate use. There did not appear to be a significant palliative benefit nor any significant change in bone resorption. Cancer 2010. © 2009 American Cancer Society.
Matti Narkia

Safety of vitamin D3 in adults with multiple sclerosis -- Kimball et al. 86 (3): 645 --... - 0 views

  •  
    Safety of vitamin D3 in adults with multiple sclerosis.
    Kimball SM, Ursell MR, O'Connor P, Vieth R.
    Am J Clin Nutr. 2007 Sep;86(3):645-51.
    PMID: 17823429

    Conclusions: Patients' serum 25(OH)D concentrations reached twice the top of the physiologic range without eliciting hypercalcemia or hypercalciuria. The data support the feasibility of pharmacologic doses of vitamin D3 for clinical research, and they provide objective evidence that vitamin D intake beyond the current upper limit is safe by a large margin.
Matti Narkia

Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated... - 0 views

  •  
    Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
    Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.
    Circ J. 2009 Jul;73(7):1283-90. Epub 2009 May 8.
    PMID: 19423946

    Conclusions: EPA is effective for secondary prevention of CAD, especially in individuals with prior MI, and
    should be added to conventional treatment.
Matti Narkia

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic pati... - 0 views

  •  
    Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
    Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators.
    Lancet. 2007 Mar 31;369(9567):1090-8. Erratum in: Lancet. 2007 Jul 21;370(9583):220.
    PMID: 17398308
    doi:10.1016/S0140-6736(07)60527-3

    Interpretation
    EPA is a promising treatment for prevention of major coronary events, and especially non-fatal coronary events, in Japanese hypercholesterolaemic patients
Matti Narkia

JAMA -- Abstract: Omega-3 Augmentation of Sertraline in Treatment of Depression in Pati... - 0 views

  •  
    Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial.
    Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS.
    JAMA. 2009 Oct 21;302(15):1651-7.
    PMID: 19843899

    Conclusions Treatment of patients with CHD and major depression with sertraline and omega-3 fatty acids did not result in superior depression outcomes at 10 weeks, compared with sertraline and placebo. Whether higher doses of omega-3 or sertraline, a different ratio of EPA to DHA, longer treatment, or omega-3 monotherapy can improve depression in patients with CHD remains to be determined
Matti Narkia

Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after ... - 0 views

  •  
    Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol.
    Glendenning P, Chew GT, Seymour HM, Gillett MJ, Goldswain PR, Inderjeeth CA, Vasikaran SD, Taranto M, Musk AA, Fraser WD.
    Bone. 2009 Nov;45(5):870-5. Epub 2009 Jul 23.
    PMID: 19631774
    doi:10.1016/j.bone.2009.07.015

    Cholecalciferol supplementation resulted in a 31% greater increase in total HPLC-measured 25OHD (p=0.010) and 52% greater rise in RIA-measured 25OHD (p<0.001) of supplementation dose with than ergocalciferol equivalent an>0.05). In vitamin D-insufficient hip fracture patients, supplementation with cholecalciferol 1000 IU/day for three months was more effective in increasing serum 25OHD than an equivalent dose of ergocalciferol. However, the lack of difference in PTH lowering between calciferol treatments raises questions about the biological importance of this observation.
Matti Narkia

Vitamin K Supplementation in Postmenopausal Women with Osteopenia (ECKO Trial): A Rando... - 0 views

  •  
    Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.
    Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R.
    PLoS Med. 2008 Oct 14;5(10):e196. Erratum in: PLoS Med. 2008 Dec;5(12):e247.
    PMID: 18922041

    CONCLUSIONS: Daily 5 mg of vitamin K1 supplementation for 2 to 4 y does not protect against age-related decline in BMD, but may protect against fractures and cancers in postmenopausal women with osteopenia. More studies are needed to further examine the effect of vitamin K on fractures and cancers. Trial registration: ClinicalTrials.gov (#NCT00150969) and Current Controlled Trials (#ISRCTN61708241)
Matti Narkia

Supplementation with cholecalciferol does not improve glycaemic control in diabetic sub... - 0 views

  •  
    Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels.
    Jorde R, Figenschau Y.
    Eur J Nutr. 2009 Apr 16. [Epub ahead of print]
    PMID: 19370371
    10.1007/s00394-009-0020-3

    Conclusions We were not able to demonstrate that vitamin D supplementation had a significant effect on glucose metabolism in subjects with type 2 diabetes but without vitamin D deficiency. Further studies are needed in larger groups of subjects with type 2 diabetes or impaired glucose tolerance, who also exhibit low serum 25-hydroxyvitamin D levels.
Matti Narkia

Comparison of Daily, Weekly, and Monthly Vitamin D3 in Ethanol Dosing Protocols for Two... - 0 views

  •  
    Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients.
    Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R.
    J Clin Endocrinol Metab. 2008 Sep;93(9):3430-5. Epub 2008 Jun 10.
    PMID: 18544622
    doi:10.1210/jc.2008-0241

    CONCLUSIONS: Supplementation with vitamin D can be achieved equally well with daily, weekly, or monthly dosing frequencies. Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.
1 - 20 of 29 Next ›
Showing 20 items per page